시장보고서
상품코드
1800865

아테렉토미 기기 시장 보고서 : 제품별, 용도별, 최종사용자별, 지역별(2025-2033년)

Atherectomy Devices Market Report by Product Application, End User, and Region 2025-2033

발행일: | 리서치사: IMARC | 페이지 정보: 영문 137 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 아테렉토미 기기 시장 규모는 2024년에 10억 2,240만 달러에 달했습니다. 향후, IMARC Group은 시장이 2033년까지 15억 2,450만 달러에 달하며, 2025-2033년에 4.31%의 성장률(CAGR)을 보일 것으로 예측하고 있습니다. 말초동맥질환(PAD) 증가, 기술 발전, 노인 인구 증가, 최소침습 수술의 부상, 의료 인프라 개발, 신흥 경제국에서의 상환 정책 등이 시장 성장을 가속하는 주요 요인으로 작용하고 있습니다.

동맥류 절제술 장비 시장 동향

말초동맥질환(PAD) 환자 증가

인구 고령화, 당뇨병 및 비만 증가로 인해 전 세계에서 PAD 환자가 증가하고 있으며, 이는 동맥류 절제술 장비 시장의 성장을 촉진하고 있습니다. 미국에서는 약 800만-1,200만 명이 PAD를 앓고 있으며, 특히 50세 이상의 환자가 많고, 40세 이상 650만 명이 PAD 진단을 받았습니다. 동맥절제술은 혈관 중재술의 중요한 대안으로 동맥 플라크 제거를 위한 최소 침습적 접근법을 제공합니다. 이 장치는 혈류를 촉진하고 다리 통증, 피로 등의 증상을 완화합니다. 플라크를 직접 절단하거나 증발시킴으로써 동맥 개통성을 회복시켜 중증 PAD 환자의 예후를 크게 개선합니다.

기술 발전

동맥류 절제술 장비의 기술 혁신에는 방향 제어 장비와 고주파 회전 기술의 등장이 있으며, 이러한 장비의 효과와 안전성을 향상시키고 있습니다. 예를 들어 2020년 연구에 따르면 궤도식 죽상동맥절제술(플라크를 연마하여 제거하는 방법)은 막힌 다리 동맥을 90%의 확률로 효과적으로 뚫어주는 반면, 레이저 죽상동맥절제술은 76%의 확률로 혈류를 개선하는 것으로 나타났습니다. 이러한 환자 예후 개선과 외과 의사들의 선호도가 죽상동맥류 절제술 장비의 성장을 촉진하고 있습니다. 172명의 환자를 대상으로 한 다기관 연구에서 제트스트림은 99%의 성공률을 보였으며, 6개월 및 12개월 후 임상적 표적 병변의 재관류율은 각각 15%와 26%였습니다.

신흥 시장 진출

시장의 주요 기업은 의료 인프라 개발 및 의료비 지출 증가가 주목받는 신흥 경제 국가들에 주목하고 있으며, 이는 새로운 기회를 제공합니다. 예를 들어 브라질, 러시아, 인도, 중국, 남아프리카공화국(BRICS)의 신흥 시장은 세계 의료 분야의 의료 제품 및 서비스 수요 및 공급 상황을 점점 더 많이 형성하고 있습니다. 2030년 GDP 대비 의료비 비중은 브라질 8.4%, 러시아 5.2%, 인도 3.5%, 중국 5.9%, 남아프리카공화국 10.4%로 예측되고 있습니다. 보다 진보된 치료 옵션의 실현은 이러한 시장 진입을 가능하게 하고, 동맥류 절제술 장비의 전 세계 보급을 확대할 수 있습니다.

목차

제1장 서문

제2장 조사 범위와 조사 방법

  • 조사의 목적
  • 이해관계자
  • 데이터 소스
    • 1차 정보
    • 2차 정보
  • 시장 추정
    • 보텀업 어프로치
    • 톱다운 어프로치
  • 조사 방법

제3장 개요

제4장 서론

제5장 세계의 아테렉토미 기기 시장

  • 시장 개요
  • 시장 실적
  • COVID-19의 영향
  • 시장 예측

제6장 시장 내역 : 제품별

  • 방향 제어형 아테렉토미 기기
  • 궤도식 아테렉토미 기기
  • 포토 절제 아테렉토미 기기
  • 회전식 아테렉토미 기기
  • 지원 기기

제7장 시장 내역 : 용도별

  • 말초혈관
  • 심혈관
  • 신경혈관

제8장 시장 내역 : 최종사용자별

  • 병원
  • 외래 수술 센터
  • 연구실 및 학술기관

제9장 시장 내역 : 지역별

  • 북미
    • 미국
    • 캐나다
  • 아시아태평양
    • 중국
    • 일본
    • 인도
    • 한국
    • 호주
    • 인도네시아
    • 기타
  • 유럽
    • 독일
    • 프랑스
    • 영국
    • 이탈리아
    • 스페인
    • 러시아
    • 기타
  • 라틴아메리카
    • 브라질
    • 멕시코
    • 기타
  • 중동 및 아프리카

제10장 SWOT 분석

제11장 밸류체인 분석

제12장 Porter's Five Forces 분석

제13장 가격 분석

제14장 경쟁 구도

  • 시장 구조
  • 주요 기업
  • 주요 기업의 개요
    • Abbott Laboratories
    • Avinger
    • B. Braun Melsungen AG
    • Biomerics
    • Biotronik
    • Boston Scientific Corporation
    • C.R. Bard(Becton, Dickinson and Company)
    • Cardinal Health Inc.
    • Koninklijke Philips N.V.
    • Medtronic
    • Minnetronix Inc.
    • Straub Medical AG(Becton, Dickinson and Company)
    • Terumo Corporation
KSA 25.09.09

The global atherectomy devices market size reached USD 1,022.4 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 1,524.5 Million by 2033, exhibiting a growth rate (CAGR) of 4.31% during 2025-2033. The rise in peripheral artery disease (PAD), significant technological advancements, rising ageing population, advent of minimally invasive surgeries, development of healthcare infrastructure, and reimbursement policies in emerging economies represent some of the key factors driving the growth of the atherectomy market.

Atherectomy Devices Market Trends:

Rising Cases of Peripheral Artery Disease (PAD)

The increasing cases of PAD at a global level due to ageing population and the rise in diabetes and obesity is leading the atherectomy device market growth. Approximately, PAD affects 8 to 12 million people in the United States, especially in those over 50. Out of these, 6.5 million over the age of 40 are diagnosed with PAD. Atherectomy devices provide a minimally invasive approach to remove arterial plaque as it is an important alternative in vascular interventions. The device enhances blood flow and reduces symptoms such as leg pain and fatigue. By directly cutting away or vaporizing the plaque, these devices help restore arterial patency, significantly improving patient outcomes in individuals with severe forms of PAD.

Technological Advancements

Major atherectomy devices innovations include the appearance of directionally controlled devices and high-frequency rotational technologies, which have continued to improve the effectiveness and safety of these devices. For instance, a 2020 study suggests that orbital atherectomy (which sands down plaque) effectively opens up blocked leg arteries 90 percent of the time, while laser atherectomy achieves similarly improved blood flow 76 percent of the time. These improvements in patient outcome and surgeon preference for these devices are propelling the growth of the atherectomy devices. In a multicenter study of 172 patients, Jetstream use had a 99% device success, and six-month and 12-month clinically-driven, target-lesion revascularization rates of 15% and 26%, respectively; with a one-year restenosis rate of 38% based on duplex imaging.

Expansion into Emerging Markets

Prominent key players are focusing on emerging economies where healthcare infrastructure development and growing healthcare spending is focused, thereby creating new opportunities for the key players in the market. For instance, the emerging markets of Brazil, Russia, India, China, and South Africa (BRICS) are increasingly shaping the landscape of the global health sector demand and supply for medical goods and services. Health spending as a percentage of GDP in 2030 is projected as - Brazil, 8.4%; Russia, 5.2%; India, 3.5%; China, 5.9%; South Africa, 10.4%. The penetration into these markets is enabled by realization of more advanced treatment alternatives, thus expanding the global footprint of atherectomy devices.

Atherectomy Devices Market Segmentation:

Breakup by Product:

  • Directional Atherectomy Devices
  • Orbital Atherectomy Devices
  • Photo-Ablative Atherectomy Devices
  • Rotational Atherectomy Devices
  • Support Devices

Directional Atherectomy Devices accounts for the majority of the market share

Directional atherectomy devices are created to precisely eliminate atherosclerotic plaque from obstructed arteries. These instruments provide the possibility of accurate control, which reduces vessel wall trauma, an important aspect for patient safety and recovery. Their ability to treat complex lesions in multiple vessel sizes makes them to be favoured by vascular specialists leading to the growth of the product segment. The capability of the devices to collect and remove plaque during the procedure sets these devices apart and is in a number of clinical situations preferable.

Breakup by Application:

  • Peripheral Vascular
  • Cardiovascular
  • Neurovascular

Peripheral Vascular accounts for the majority of the market share

The use of atherectomy devices in the treatment of peripheral vascular diseases is important because of the growing prevalence of PAD. Such devices play a key role in reestablishing the blood flow in leg arteries thus help to relieve the symptoms such as pain and mobility problems. The demand in this segment is determined by minimally invasive character of the procedure which allows short recovery period and lower risks of complications in comparison to conventional surgery making patient outcomes and treatment efficiencies higher.

Breakup by End User:

  • Hospitals
  • Ambulatory Surgery Centers
  • Research Laboratories and Academic Institutes

Hospitals accounts for the majority of the market share

Hospitals are the main users of atherectomy devices because these procedures are very complex and need advanced infrastructure and highly trained healthcare professionals. The growth of the segment is followed by the growth of the number of vascular surgeries conducted in hospitals, fueled by investments into advanced technologies and in the training programs of health providers. Ability of hospitals to offer all types of care including post-operative requirements also helps in making them the dominant subject in the market.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America dominates the market

The report has also provided a comprehensive analysis of all the major markets which include North America (United States, Canada); Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others); Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others); Latin America (Brazil, Mexico, Others), and Middle East and Africa. According to the report, North America was the largest market for atherectomy devices.

North America is the largest market for atherectomy because of high prevalence of cardiovascular diseases, developed healthcare system and the key market players in the region. The United States is the biggest market in this region because of the favourable reimbursement scenarios, clinical trials, and solid governmental support for research and development in advanced medical devices. The commitment of the region to application of new healthcare solutions is driving the market growth.

Competitive Landscape:

  • The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have been provided. Some of the major market players in the atherectomy devices market include Abbott Laboratories, Avinger, B. Braun Melsungen AG, Biomerics, Biotronik, Boston Scientific Corporation, C.R. Bard (Becton, Dickinson and Company), Cardinal Health, Koninklijke Philips N.V., Medtronic, Minnetronix Inc., Straub Medical AG (Becton, Dickinson and Company), and Terumo Corporation.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

  • There is a dynamic market in atherectomy devices with the use of evolving strategies by major players in pursuit to grow their market share and to satisfy the increasing demand for minimally invasive surgery alternatives. One of these approaches is technical oriented, which is to say that the companies invest significantly in R&D to improve their devices that become therefore more efficient and safer. The second common event is strategic alliances and collaborations that support knowledge sharing and better distribution channels. In addition, mergers and acquisitions are common enabling companies to expand their product portfolios and geographical coverage. Approvals by regulatory bodies play an important role here as the companies are trying to meet tough norms that guarantee the efficiency and safety of their products in many markets.

Key Questions Answered in This Report

  • 1.What was the size of the global atherectomy devices market in 2024?
  • 2.What is the expected growth rate of the global atherectomy devices market during 2025-2033?
  • 3.What has been the impact of COVID-19 on the global atherectomy devices market?
  • 4.What are the key factors driving the global atherectomy devices market?
  • 5.What is the breakup of the global atherectomy devices market based on the product?
  • 6.What is the breakup of the global atherectomy devices market based on the application?
  • 7.What is the breakup of the global atherectomy devices market based on the end user?
  • 8.What are the key regions in the global atherectomy devices market?
  • 9.Who are the key players/companies in the global atherectomy devices market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Atherectomy Devices Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Directional Atherectomy Devices
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Orbital Atherectomy Devices
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Photo-Ablative Atherectomy Devices
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Rotational Atherectomy Devices
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Support Devices
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Peripheral Vascular
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Cardiovascular
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Neurovascular
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Ambulatory Surgery Centers
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Research Laboratories and Academic Institutes
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbott Laboratories
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Avinger
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
    • 14.3.3 B. Braun Melsungen AG
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Biomerics
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Biotronik
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Boston Scientific Corporation
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 C.R. Bard (Becton, Dickinson and Company)
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 Cardinal Health Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Koninklijke Philips N.V.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Medtronic
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
    • 14.3.11 Minnetronix Inc.
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
    • 14.3.12 Straub Medical AG (Becton, Dickinson and Company)
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
    • 14.3.13 Terumo Corporation
      • 14.3.13.1 Company Overview
      • 14.3.13.2 Product Portfolio
      • 14.3.13.3 Financials
      • 14.3.13.4 SWOT Analysis
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제